News & Events
Find out more about dates & events, the progress of our vaccine research and all the other interesting news on the topic.
News
11 July 2023
Verovaccines enters company growth phase
- Vaccine developer completes the validation of its vaccine and manufacturing platforms.
- Company to focus now on development to bring new vaccines to market quickly. Another swine vaccine enters pipeline.
14 December 2022
EU fördert Mitarbeiterweiterbildung
Auch im Jahr 2022 wurde die Weiterentwicklung der VEROVACCiNES GmbH vorangetrieben. Mit Hilfe einer Förderung der beruflichen Weiterbildung von Beschäftigten in Unternehmen aus Mitteln des Europäischen Sozialfonds (ESF) konnten mehrere Mitarbeiter in den Bereichen „Good Manufacturing Practice“ und „Good Laboratory Practice“ weitergebildet werden. Mit diesen Maßnahmen wird das Qualitätsniveau weiter gehoben.
12 October 2022
Verovaccines paves way for manufacturing its vaccines
- Verovaccines upscales manufacturing processes of its yeast-based vaccines to industrial scale
- This is an important milestone on the road to commercialization of this novel vaccine class
24 March 2022
VEROVACCiNES is now using a twin fermenter – many thanks to INFORS HT
The new twin-fermenter will enable us to boost the number of fermentation runs in order to
- speed up optimization of manufacturing (upstream processing)
- generate quality data for our K. lactis yeast system (run-to-run consistency: biomass yield, antigen content, process reliability…)
- produce vaccine material for efficacy and safety trials under highly controlled conditions
17 February 2022
VEROVACCiNES establishes Advisory Board and fills key position
- Verovaccines establishes advisory board with internationally experienced members from the vaccine world
- Ulrike Diesterbeck, DVM takes over the position of Head of Development
- The aim is to accelerate in-house vaccine development and bring new animal vaccines to market faster
14 October 2021
VEROVACCiNES closes Series B financing with consortium of investors from Germany and Switzerland
- Vaccine specialist closes Mid-Seven-Figure Series B Financing Round
- Shareholder group expanded by four new investors with important expertise
- The fresh funding will be used to drive several vaccine programs into regulatory development
21 August 2021
Verovaccines promotes the expertise of its Quality Assurance (Q/A) staff through continuing education/training
This is supported e.g. by the European structural and investment funds.
This allowed one employee to successfully attend a course on GMP auditing, which strengthens us in view of the upcoming production of our vaccines on an industrial scale under GMP conditions.
4 March 2021
Verovaccines Achieves Full Protection of Target Animals Against Viral Challenge in its 4th Animal Vaccine Program
- Validation of novel, cost-effective, multi-valent animal vaccines with high safety and efficacy
- Results extend usability of the Company’s platform in the poultry sector
- Progeny fully protected against viral infection
30 November 2020
Eligibility of investor investments under the BMWi’s INVEST programm
Verovaccines GmbH receives BAFA certification that it meets all the requirements for eligible investor participation. This means that investors can benefit from an acquisition grant and an exit grant when investing in the company.
11 February 2020
Vaccine developer Verovaccines concludes further pharmaceutical cooperation
- Verovaccines GmbH concludes the second cooperation with an internationally operating veterinary pharmaceutical company
- The cooperation aims at the joint development of a veterinary vaccine based on the proprietary technology platform
3 December 2019
Verovaccines concludes international pharma cooperation agreement
- Verovaccines enters into first collaboration with a Japanese pharmaceutical company to jointly develop a veterinary vaccine
- The goal is to develop and commercialize novel, cost-effective vaccines with high safety and efficacy for animal health
- The company was financed for the seed phase by High-Tech Gruenderfonds, Business Angels and the founders as well as a seven-figure GO-Bio grant
1 June 2019
Film about the Verovaccines funding project
This documentation (audio in German) by the German GO-Bio funding program (https://go-bio.de/en) gives a short introduction to yeast-based vaccines for animal health. GO-Bio is a life sciences-oriented funding initiative of the Federal Ministry of Education and Research of Germany.
17 July 2018
Moving to a new facility
VEROVACCiNES GmbH recently moved to a new facility on the Technology Center/Weinberg Campus in Halle (Saale), Germany. The 400 square meter facility provides state of the art laboratories for molecularbiology applications (biochemistry, microbial fermentation, recombinant technology and tissue culture). The labs provide significantly more space for the company. This will allow further growth and the development of yeast-based subunit marker vaccines in a faster and more effective way.
17 April 2018
3.1 million euro public funding granted to VEROVACCiNES GmbH for animal vaccine development.
VEROVACCiNES GmbH has been awarded 3.1 million euro research funding from the highly competitive funding program GO-Bio (German Federal Ministry of Education and Research) for a 3 year period. „This support will take the development of our yeast-based vaccines a significant step forward. We expect to fully validate our novel technology to generate multivalent vaccines and to further develop the according vaccine candidates.“ adds Prof. Dr. Sven-Erik Behrens, CSO of VEROVACCiNES GmbH.
17 July 2017
VEROVACCiNES GmbH founded in Halle (Saale), Germany.
VEROVACCiNES GmbH is a successful spin-off from the Martin Luther University Halle-Wittenberg, Germany. The co-founders Dr. Hanjo Hennemann and Prof. Dr. Sven-Erik Behrens entered the management of the company as managing directors. “We are very pleased to get the company started. After achieving a positive votum for our funding application in the federal BMBF GO-Bio-funding program, making VEROVACCiNES eligible for 3.1 m euros funding, it made sense to get the company off the ground. We plan to close the financing round soon and to continue the development of our vaccine programs.” Dr. Hanjo Hennemann said.
14 April 2017
Fourth vaccine program (bovine viral diarrhea) validated in initial proof of concept study
VEROVACCiNES successfully completed trials in its bovine viral diarrhea (BVD) program. “This proof of concept study indicates efficacy of our vaccine candidate in the target animal, though the obtained data require statistical coverage”, Prof. Sven-Erik Behrens said. After having achieved full protection with proprietary subunit marker vaccines in its infectious bursitis-, influenza- and an undisclosed swine program, data from this fourth program strengthen the validation basis further and extends the applicability of VEROVACCiNES technology.
22 February 2017
VEROVACCiNES selected as Emerging Company at ANIMAL HEALTH INVESTMENT Europe, London UK conference 2017.
The selection committee of the conference ANIMAL HEALTH INVESTMENT Europe, London UK, selected the startup project VEROVACCiNES as one of 12 presenting emerging companies. VEROVACCiNES is the only “yet to be founded” participant.
This conference is dedicated to showcasing to investors the most innovative emerging animal health companies covering the companion, aquaculture and production animal space.
Events
07 January 2023
2023, March 06. – 08. Animal Health Innovation Europe, London
Animal Health, Nutrition and Technology Innovation Europe is the sector’s premier innovation summit, showcasing the most exciting emerging companies and connecting them with investors and strategic partners. And we will be there again!
12 October 2022
Animal AgTech Innovation Summit 2022, Amsterdam
We will be attending the summit also this year. We are excited to discuss new innovations, collaborations and partnerships with you. Come and reach out to us.
11 October 2022
World Vaccine Congress in Barcelona
Dr. Hanjo Hennemann will present Verovaccines subunit vaccine platform in the workshop „Platform Technologies“. The workshop will highlight different vaccine technologies (BioNTech, Curevac, ZAPI, CEPI, Verovaccines) and feedback from the regulatory perspective (EMA-TBC, Paul-Ehrlich-Institute). Meet us at the conference!
07 September 2022
11th Leipzig Veterinary Congress 2022
We will be attending this year’s Leipzig Veterinary Congress. We are looking forward to an update on the needs in the animal health field, extending the professional network and learning about new applications of our vaccine technology.
22 January 2022
2022, Feb 22. – 23.: Animal Health Innovation Europe
A planned face-to-face conference will take place in London on 22-23 February 2022.
We look forward to meeting our business partners in person again.
19 September 2021
2021, Oct 19. – 20.: Animal AgTech Innovation Summit
The Animal AgTech Innovation Summit will take place for the third time on 19 and 20 October and we were there from the very beginning. Of course, we won’t miss it this time either. We look forward to seeing you there – even if digitally again.
21 July 2021
2021, Aug 18. – 19.: Animal Health Innovation Latin America
In addition to Animal Health Innovation in Europe, we are also expanding our view to Latin America. We are excited to see what awaits us there.
8 March 2021
Animal AgTech Innovation Summit
Everything becomes virtual! Also at this summit, we are there for you online and would like to get in contact with you in the area of animal health.
9 February 2021
2021, Feb 9-12: EuroTier digital
EuroTier in Hannover is the world’s largest trade fair for animal husbandry and management. We look forward to meeting you online and talking about new products and innovations.
15 December 2020
Animal Health Innovation Conference
The Animal Health Innovation Europe (22-23 Feb 2021) is an international conference to network with innovators in animal health and nutrition and connecting those businesses with financial investors and strategic corporate partners.
Meet us there!
12 October 2020
2020, Nov 12-14: 98th and 99th Symposium on Poultry Diseases, online
20 September 2020
2020, Oct 20-21: PDA Europe Virtual Conference – Aseptic Animal Health, online
At the PDA Europe Virtual Conference – Aseptic Animal Health, Dr. Hanjo Hennemann, managing director of Verovaccines GmbH, gives an invited talk about K. lactis-based subunit vaccines. He explains technology and validation of this novel vaccine class in animal health.
The Parenteral Drug Association (PDA) is a non-profit organization, committed to developing scientifically sound, practical technical information and expertise to advance pharmaceutical/biopharmaceutical manufacturing science and regulation.
15 December 2019
2020, Jan 15: Animal Health Investment Europe, London
1 September 2019
2019, Oct. 1-2: Animal AgTech Innovation Summit, Amsterdam
24 March 2019
2019, June 24-26: VetHealth Global 2019, Charlottetown, PEI, Canada
26 January 2019
2019, Feb. 26-27: Animal Health Investment Europe 2019
29 September 2018
2018, Oct. 29-31: VEROVACCiNES GmbH to present at the 18th Annual World Vaccine Congress, Lisbon, Portugal.
The World Veterinary Vaccine Congress brings animal health industry experts from the whole value chain under one roof to discuss scientific, regulatory and commercial issues from new innovative vaccine technologies to emerging disease.
Come and see us!
12 March 2017
2017, June 12-14: VEROVACCiNES presents as selected emerging company at VETHEALTH GLOBAL 2017
22 January 2017
2017, Feb. 22-23: VEROVACCiNES selected as Emerging Company at ANIMAL HEALTH INVESTMENT Europe, London UK conference 2017.
This conference is dedicated to showcasing to investors the most innovative emerging animal health companies covering the companion, aquaculture and production animal space.
